Rationale Design of Phase 1 Trial Combining Oncolytic Virotherapy with CAR-T Cells

Time: 2:30 pm
day: Day Two


  • CAR-T therapy of solid tumors is limited by tumor microenvironments that exclude and suppress T cells such as huCART-meso cells targeting mesothelin
  • VCN-01, a PH20 hyaluronidase-armed Oncolytic Virus degrades tumor extracellular matrix, reprograms the tumor microenvironment, and draws T cells into tumor lesions
  • We designed a combination trial NCT05057715 to establish the safety, feasibility, and preliminary efficacy of a combination of huCART-meso cells and VCN-01 in patients with pancreatic or ovarian cancer